Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.54 |
| ▸ | PIM1 | P11309 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ESRRA | P11474 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860639 | 1.00 | PIK3CG (0.54) | PIK3CGPIM1TDP1PTPN1ESRRA | |
| SCHEMBL12978775 | 1.00 | PIK3CG (0.54) | PIK3CGPIM1TDP1PTPN1ESRRA | |
| SCHEMBL12978788 | 0.91 | PIK3CG (0.47) | PIK3CGPIM1TDP1HPGDPIM2 | |
| SCHEMBL860312 | 0.91 | PIK3CG (0.47) | PIK3CGPIM1TDP1HPGDPIM2 | |
| SCHEMBL860313 | 0.91 | PIK3CG (0.47) | PIK3CGPIM1TDP1HPGDPIM2 | |
| SCHEMBL860026 | 0.89 | PIK3CG (0.52) | PIK3CGPIM1TDP1HPGDAKR1B1 | |
| SCHEMBL860025 | 0.89 | PIK3CG (0.52) | PIK3CGPIM1TDP1HPGDAKR1B1 | |
| SCHEMBL12978957 | 0.89 | PIK3CG (0.52) | PIK3CGPIM1TDP1HPGDAKR1B1 | |
| SCHEMBL12769034 | 0.81 | ERN1 (0.51) | PIK3CG | |
| SCHEMBL14679081 | 0.79 | GABRG2 (0.37) | PIK3CGTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2432473-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIK3CG 415/4885PIM1 1/4885TDP1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.